We found that increasing HIF activity by FIH deletion boosts effector differentiation and anti-tumour activity, but further increasing HIF activity, through combined FIH and VHL deletion, results in suppression of proliferation, reduced interferon-gamma production, and removes the in vivo anti-tumour advantage conferred by FIH KO T cells. The gene discussed is IFNG; the disease is neoplasm.